Intech Investment Management LLC Purchases New Shares in MaxCyte, Inc. (NASDAQ:MXCT)

Intech Investment Management LLC purchased a new position in MaxCyte, Inc. (NASDAQ:MXCT) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 13,114 shares of the company’s stock, valued at approximately $51,000.

Other large investors also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its stake in shares of MaxCyte by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company’s stock valued at $79,000 after buying an additional 7,930 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in MaxCyte by 20.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company’s stock worth $106,000 after acquiring an additional 4,320 shares in the last quarter. Creative Planning increased its position in shares of MaxCyte by 33.6% during the third quarter. Creative Planning now owns 28,652 shares of the company’s stock worth $111,000 after acquiring an additional 7,212 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of MaxCyte by 22.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company’s stock valued at $128,000 after acquiring an additional 5,927 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of MaxCyte by 84.5% in the 3rd quarter. SG Americas Securities LLC now owns 37,969 shares of the company’s stock worth $148,000 after buying an additional 17,385 shares during the period. 68.81% of the stock is owned by institutional investors.

MaxCyte Price Performance

NASDAQ:MXCT opened at $3.60 on Monday. The firm has a market cap of $380.48 million, a PE ratio of -10.59 and a beta of 1.37. The company has a 50-day moving average of $3.64 and a 200 day moving average of $4.07. MaxCyte, Inc. has a 1-year low of $3.16 and a 1-year high of $5.55.

MaxCyte (NASDAQ:MXCT) last posted its earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The company had revenue of $8.16 million for the quarter, compared to analyst estimates of $7.50 million. During the same quarter in the previous year, the firm earned ($0.11) earnings per share. Sell-side analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

Insider Buying and Selling at MaxCyte

In related news, Director Stanley C. Erck sold 21,607 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total value of $80,161.97. Following the completion of the transaction, the director now owns 269,118 shares in the company, valued at $998,427.78. This trade represents a 7.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last ninety days, insiders sold 27,607 shares of company stock worth $102,782. 3.00% of the stock is owned by insiders.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.